Compare prices and buy Semax + Selank Blend from 15 research peptide vendors - also called suppliers or sources. Updated daily.
Combines Semax, the ACTH(4-7) fragment extended with the stabilizing tripeptide Pro-Gly-Pro and studied in rodents for neurotrophic and neuroprotective effects, with Selank, the same extension applied to the immune tetrapeptide tuftsin and studied as an anxiolytic. The pairing is a market convention rather than a demonstrated pharmacological one, and no published study has tested the two peptides together. Vendors that state the split mostly divide a vial equally by mass, the blend also comes as pre-mixed sprays and dropper bottles, and it is sold for research use only.
For research purposes only. Not medical advice.
The Semax + Selank blend puts two Russian research peptides in one vial, nasal spray or dropper bottle: Semax, Met-Glu-His-Phe-Pro-Gly-Pro, and Selank, Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a mixture, so it carries no CAS number of its own.
Both heptapeptides came out of the Institute of Molecular Genetics of the Russian Academy of Sciences, and both end in Pro-Gly-Pro, a tripeptide tail that slows enzymatic breakdown. Semax is ACTH(4-7) plus that tail, and the FDA's 2026 review describes it as an analog of ACTH(4-10) that differs in the last three residues. Selank attaches the same tail to tuftsin, a four-residue fragment of immunoglobulin G.
Vendors that state the split mostly divide the vial equally by mass. At least one sells a larger vial holding three parts Selank to one part Semax.
Nearly all of each component's evidence is preclinical or small Russian clinical work. In rats, a single intranasal application of Semax raised hippocampal BDNF protein 1.4-fold (Dolotov and colleagues, Brain Research, 2006), and the FDA's 2026 review summarized rodent work in which it acted as a neuroprotectant, anticoagulant and analgesic "through poorly understood mechanisms of action." Selank's preclinical work points to GABAergic signaling, including gene-expression changes in the rat frontal cortex (Volkova and colleagues, 2016) and a brain-membrane binding study reporting that it modulates GABA binding allosterically (Vyunova and colleagues, 2018).
The one mechanism the two share was measured on each peptide separately. Kost and colleagues reported in 2001 that both inhibit the enkephalin-degrading enzymes of human serum in vitro.
A PubMed search for records naming both peptides, run in October 2026, found no study that gave the two together, and ClinicalTrials.gov lists no registered study of either. The closest, a 2020 brain-imaging study in healthy volunteers, gave them to separate groups (Panikratova and colleagues).
The case vendors make for the blend is assembled from single-compound studies, setting Semax's cognition research beside Selank's anxiety research. The combination data that do exist for Selank paired it with benzodiazepines, diazepam in chronically stressed rats (Kasian and colleagues, 2017) and phenazepam in Russian patients with anxiety disorders (Medvedev and colleagues, 2015). Neither drug is in this vial, no trial has evaluated Semax with Selank, and the pairing is a market convention rather than a pharmacological one.
N-Acetyl Semax and N-Acetyl Selank are different molecules indexed as separate rows, and most blend titles do not say which form is inside. Product pages disagree. Some print the plain sequences and CAS numbers, while one page titled Semax/Selank lists the formula of N-acetyl Semax amidate, C39H54N10O10S, where plain Semax is C37H51N9O10S. Even the two Semax nominations the FDA reviewed were unclear about the form, with a certificate naming the acetate salt in its title and the free base by its CAS number and formula. The formula or mass reported for each component on the certificate of analysis is the only check.
PeptideScouter records a blend's size as the vial's total peptide content, so an equal split benchmarks against the simple average of the two component prices, as on the CJC-1295 + Ipamorelin page. Semax and Selank index close to each other per milligram, so even the lopsided vial lands near that benchmark, and a blend that looks cheap usually reflects a larger vial.
As of October 2026 neither component holds an FDA approval. Both are registered medicines in Russia, according to the FDA's 2026 review for Semax and a 2022 review in Pharmaceutics, which lists Selank as an anxiolytic.
Their US compounding records start together and split.
The vote is advisory, and as of October 2026 neither peptide is on the 503A bulks list and the committee has not heard Selank. Neither peptide is named on WADA's Prohibited List, and the WADA list explainer covers why that alone does not settle their status in sport. Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
Two heptapeptides developed at the same Russian institute, combined in one product. Semax is Met-Glu-His-Phe-Pro-Gly-Pro, CAS 80714-61-0, and Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, CAS 129954-34-3. Vendors that state the split mostly divide a vial equally by mass, and at least one sells a vial holding three parts Selank to one part Semax. The blend is also sold as pre-mixed nasal sprays and dropper bottles. Because it is a mixture, it has no CAS number of its own. Material sold by research peptide vendors is offered for laboratory use only and not for human consumption.
Not as a combination, as of October 2026. A PubMed search for records naming both peptides found no study that gave them together, and ClinicalTrials.gov lists no registered study of either one. The closest is a 2020 Russian brain-imaging study in 52 healthy volunteers that gave Semax, Selank or placebo to separate groups. The combination work that does exist for Selank paired it with benzodiazepine drugs, diazepam in rats and phenazepam in patients with anxiety disorders. Neither study included Semax.
Most product titles do not say. N-Acetyl Semax and N-Acetyl Selank carry an acetyl group at the N-terminus, and their amidate versions also carry an amide at the C-terminus, so they are different molecules with different formulas. Some vendors print the plain sequences and CAS numbers for their blend, while at least one blend page lists the formula of N-acetyl Semax amidate, C39H54N10O10S, in place of plain Semax, C37H51N9O10S. The formula or mass reported for each component on the certificate of analysis is the only reliable check. PeptideScouter indexes the plain and N-acetyl forms as separate rows.
PeptideScouter computes a per-milligram price only for vials. Nasal sprays and dropper bottles of this blend are pre-mixed solutions sold by the bottle, so they appear in the price table at their package price but stay out of per-milligram comparisons. A solution's price also covers the liquid it is dissolved in and the delivery device, so dividing it by the peptide content would not compare like for like with a vial of powder.
No. Nominations to the Section 503A bulk drug substances list are made per substance and per proposed use, and no combination product was before the compounding advisory committee. The FDA's July 2026 review of Semax noted that US clinics and online retailers market it alone and in combination with Selank, but it evaluated Semax by itself, for cerebral ischemia, migraine and trigeminal neuralgia. On July 24, 2026 the committee voted 8 to 5 to recommend adding Semax to the list, a non-binding recommendation. Selank acetate left the FDA's Category 2 list in September 2024 after its nominator said it intended to nominate a different substance, and the committee has not heard it. None of this applies to research-grade material sold by peptide vendors.
Semax + Selank Blend is sold by 15 research peptide vendors indexed on PeptideScouter, with 31 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 15 indexed research peptide vendors currently have Semax + Selank Blend in stock. Stock state is refreshed daily from each vendor's catalog.
Studz Peptides currently lists Semax + Selank Blend at $2.50/mg, the lowest listed price across 15 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.25/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 15 vendors listing Semax + Selank Blend publish a PeptideScouter code, worth 10% to 20% off. Applied, the lowest effective price falls from $2.50/mg listed to $2.25/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Semax + Selank Blend ranges from $2.50/mg to $8.50/mg across 31 listings from 15 research peptide vendors, normalized to USD per milligram and refreshed daily.
15 research peptide vendors currently list Semax + Selank Blend on PeptideScouter. We track 31 listings across size and kit variants.
